 Longeveron Inc. NASDAQ: LGVN announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B. What Happened: Florida-based Longeverson said it has entered into a sponsored clinical research agreement with Japans National Center for Geriatrics and Gerontology and the Juntendo University Hospital to study Lomcecel-B in older, frail Japanese subjects. 